By Ana Espino | Published on February 16, 2026 | 3 min read
Acute lymphoblastic leukemia (ALL)
is the most common cancer in children, accounting for approximately 80% of
pediatric leukemias. It is characterized by the massive proliferation of
immature lymphoblasts in the bone marrow, disrupting normal hematopoiesis and
leading to potentially fatal complications without prompt treatment. Owing to
therapeutic advances, survival rates now exceed 85%. However, this success
still conceals significant limitations in disease management.
Nearly
one-third of high-risk patients develop refractory or relapsing disease, often
associated with complex molecular alterations and immune escape mechanisms.
Current strategies, based on intensive chemotherapy or targeted
immunotherapies, face limitations related to toxicity, resistance, and
insufficient patient stratification. A critical unmet need remains: the
identification of novel molecular biomarkers to refine prognosis and enable
more personalized therapeutic approaches.
In this context, sialic
acids—terminal components of glycans on the cell surface—are emerging as
potential modulators of tumor progression. Their role in cell adhesion,
signaling, and immune evasion may position them as innovative therapeutic
targets. This study was designed to assess the functional involvement of sialic
acids in pediatric ALL by analyzing their expression, biological impact, and
potential value as therapeutic targets or biomarkers in aggressive disease
forms.
Are sialic acids invisible
accomplices?
The authors conducted a structured
narrative review based on in vitro studies, animal models, and clinical data
analyses. They examined the expression of different forms of sialic acids
(Neu5Ac, Neu5Gc) and their transporters (such as SLC17A5), as well as enzymes
regulating their metabolism, particularly sialyltransferases (STs).
The findings indicate that leukemic
cells exhibit membrane hypersialylation, notably through increased α2,3- and α2,6-linked sialic acids. This alteration of the
tumor glycocalyx promotes abnormal adhesion to the bone marrow
microenvironment, enhances tissue invasion, and suppresses immune responses,
particularly by inhibiting natural killer (NK) cell activation.
The study also highlights the role
of specific transporters, such as SLC17A5, involved in intracellular sialic
acid accumulation, which may disrupt cellular metabolism and lymphoblast
differentiation. Transcriptomic database analyses (TCGA, GEO) reveal overexpression
of these enzymes in aggressive ALL subtypes.
Experimental studies further suggest
that inhibitors of sialyltransferases or enzymes capable of modifying
glycosylated structures could help restore anti-tumor immune responses, paving
the way for innovative combination therapies.
Can one excess sugar alter
prognosis?
Pediatric ALL remains a major
challenge in hematology despite generally high survival rates. The principal
obstacle is the risk of relapse and the persistence of resistant forms,
particularly in high-risk children. This study aimed to explore the role of
sialic acids in leukemic progression and to identify novel therapeutic avenues
targeting this glycosylation signature.
The collected data suggest that
hypersialylation of leukemic cells actively contributes to their survival and
immune evasion by influencing adhesion, signaling, and immune interactions.
Sialic acids may therefore represent promising prognostic biomarkers and
therapeutic targets, especially within a personalized medicine framework.
Nevertheless, several limitations
remain and justify further research. Future studies should validate these
findings in larger pediatric cohorts, functionally assess the impact of
sialylation changes on tumor progression, and develop selective, safe, and
effective inhibitors. Integrating these approaches into combination strategies
with current treatments will also be essential to enhance immune responses and
reduce relapse rates.
About the author – Ana Espino
PhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions through impactful communication.
